Pink SheetEisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
ScripRoche has unveiled promising Phase Ib/IIa trial results suggesting its “brain shuttle” Alzheimer’s disease candidate trontinemab could be safer and more effective than approved therapies, and will beg
Generics BulletinOrganon believes there is “considerable growth potential” for the Tofidence (tocilizumab-bavi) biosimilar to Genentech’s Actemra, after acquiring rights in the US for the product from Biogen, in a dea